Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More GRAS DHA for Martek

This article was originally published in The Tan Sheet

Executive Summary

FDA affirms an alternative form of alga-derived docosahexaenoic acid for food applications, (different from the alga used in fortified infant formulas) as generally recognized as safe, Martek Biosciences announces March 3. Martek currently is in talks with food manufacturers to include the oil in cheese, yogurt and nutrition bars, and is hopeful their first DHA-containing food product will be out in 2004. The Columbia, Md.-based firm acquired the technology to make food-specific DHA via its 2003 purchase of OmegaTech (1"The Tan Sheet" April 1, 2003, p. 3)...

You may also be interested in...



Martek Expands Access To DHA Food, Beverage Market With OmegaTech Buy

Martek Biosciences is looking to gain greater access to the nascent DHA-fortified food and beverage market with the acquisition of Boulder, Colo.-based OmegaTech

'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.

Perrigo’s Albuterol Advantage Blunted By Recall

After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel